Therapeutic strategy and significance of serum rheumatoid factor in patients with rheumatoid arthritis during infliximab treatment
Open Access
- 1 January 2010
- journal article
- Published by Japan Society for Clinical Immunology in Japanese Journal of Clinical Immunology
- Vol. 33 (3) , 135-141
Abstract
To predict the response of patients with rheumatoid arthritis (RA) to infliximab, patient profile and laboratory findings were compared to determine whether there was any association with the clinical course of the disease, and the clinical significance of serum rheumatoid factor (RF) in the response to this treatment was considered. Sixty-two RA patients were treated with infliximab, 87.9% of whom were positive for RF. At baseline and 12 months after the start of treatment, RF titers were significantly lower in the low-CRP group (CRP at 12 months1.5 mg/dl). Furthermore, at baseline and 12 months, RF titers were significantly lower in the good-CRP-response group (ΔCRP≥1.5 mg/d) compared with the poor-CRP-response group (ΔCRP≤0.3 mg/d). The percent changes in RF and CRP from baseline were correlated throughout the clinical course. The duration of disease in good-CRP-response group was shorter than that in poor-CRP-response group significantly. The rate of positivity for HLA-DR4 in good response group tends to be higher than that in poor-CRP-response group. We concluded that several factors, including disease duration, positivity for HLA-DR4, and the serum RF titer at baseline, might predict the patient response to infliximab.Keywords
This publication has 21 references indexed in Scilit:
- On The Occurrence Of A Factor In Human Serum Activating The Specific Agglutintion of Sheep Blood CorpusclesAPMIS, 2007
- Association of Anti‐Cyclic Citrullinated Peptide Antibodies, Anti‐Citrullin Antibodies, and IgM and IgA Rheumatoid Factors with Serological Parameters of Disease Activity in Rheumatoid ArthritisAnnals of the New York Academy of Sciences, 2005
- Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- Infliximab treatment for rheumatic disease: clinical and radiological efficacyAnnals of the Rheumatic Diseases, 2002
- Anti-tumour necrosis factor (TNF) α treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13Annals of the Rheumatic Diseases, 2002
- Anti-Cytokine Therapy for Rheumatoid ArthritisAnnual Review of Medicine, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988